{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'For the purposes of study eligibility, limited stage disease SCLC (LD-SCLC) is defined as', 'a disease confined to the hemithorax of origin, with or without the involvement of', 'regional lymph nodes, including ipsilateral and contralateral hilar, ipsilateral and', 'contralateral mediastinal, and ipsilateral supraclavicular nodes. Extensive stage disease', 'SCLC (ED-SCLC) is defined as all other SCLC.', 'Subjects must meet all of the inclusion and none of the exclusion criteria to be eligible for', 'this study. Eligibility criteria may not be waived by the Investigator and are subject to', 'review in the event of a Good Clinical Practice (GCP) audit and/or regulatory authority', 'inspection.', '5.2.1', 'Inclusion Criteria', '1.', \"Subject or the subject's legally acceptable representative must voluntarily sign and\", 'date an informed consent, approved by an Independent Ethics Committee', '(IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or', 'study-specific procedures and should be willing and able to comply with', 'parameters as outlined in the protocol.', '2.', 'Subject must be > 18 years of age.', '3.', 'Histologically or cytologically confirmed ED SCLC (extensive stage disease at', 'initial diagnosis), with ongoing clinical benefit (SD, PR, or CR per RECIST v.1.1)', 'following completion of 4 cycles of first-line platinum-based therapy (cisplatin or', 'carboplatin in combination with etoposide or irinotecan).', '4.', 'Subjects with a history of CNS metastases prior to the initiation of first-line', 'platinum-based therapy must have received definitive local treatment and have', 'documentation of stable or improved CNS disease status based on brain imaging', 'within 28 days prior to randomization, off or on a stable dose of corticosteroids.', '5.', 'Subject is eligible to be randomized at least 3 but no more than 9 weeks from', 'Day 1 of the fourth cycle of first-line platinum-based chemotherapy.', '34']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '6.', 'Availability of archived or representative tumor material for assessment of DLL3', 'expression.', '7.', 'Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 (Refer', 'to Appendix D).', '8.', 'Recovery to < Grade 1 of any clinically significant toxicity (excluding alopecia)', 'prior to randomization.', '9.', 'Subject must have adequate bone marrow, renal and hepatic function as follows:', 'a.', 'Absolute neutrophil count (ANC) > 1,000/L', 'b. Platelet count > 75,000/L', 'c. Hemoglobin > 8.0 g/dL', 'd. Serum total bilirubin V 1.5 X upper limit of normal (ULN) or < 3 X ULN for', \"subjects with Gilbert's disease\", 'e. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST)', '<3 X ULN (< 5 X ULN if evidence of hepatic involvement by malignant', 'disease)', 'f.', 'Calculated creatinine clearance > 30 mL/min by the modified Cockroft-Gault', 'formula (Refer to Appendix E)', 'g. Albumin > 3 g/dL', '10.', 'If female, subject must be either postmenopausal as defined as:', 'Age > 55 years with no menses for 12 or more months without an alternative', 'medical cause.', 'Age V 55 years with no menses for 12 or more months without an alternative', 'medical cause AND an FSH level > 40 IU/L.', 'OR', 'Permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy', 'or hysterectomy).', '35']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'OR a Woman of Childbearing Potential (WOCBP) practicing at least one protocol', 'specified method of birth control (Section 5.2.4), starting at randomization through', 'at least 6 months after the last dose of blinded investigational product.', 'If the male subject is sexually active, he must agree, from randomization through at', 'least 6 months after the last dose of blinded investigational product, to practice the', 'protocol specified contraception (Section 5.2.4).', '11.', 'Females of childbearing potential must have a negative serum pregnancy test result', 'at Screening, and a negative urine pregnancy test at randomization.', 'Females of non-childbearing potential (either postmenopausal or permanently', 'surgically sterile as defined in Section 5.2.4) at Screening do not require pregnancy', 'testing.', 'Rationale for Inclusion Criteria', '1', 'In accordance with Harmonized Good Clinical Practice (GCP)', '2 7', 'To select and/or collect data on the subject population', '8 9', 'For the safety of the subjects', '10 - 11', 'The impact of rovalpituzumab tesirine on pregnancy in humans is', 'unknown', '5.2.2', 'Exclusion Criteria', 'A subject will not be eligible for study participation if he/she meets any of the following', 'criteria:', '1.', 'Any prior systemic chemotherapy, small molecule inhibitors, immune checkpoint', 'inhibitors, other monoclonal antibodies, antibody-drug conjugates,', 'radioimmunoconjugates, T-cell or other cell-based or biologic therapies, or any', 'other anti-cancer therapy than that described in Inclusion Criteria 3 - 5 for SCLC.', '36']\n\n###\n\n", "completion": "END"}